fabV

UniProt ID: Q9HZP8
Organism: Pseudomonas aeruginosa PAO1
Review Status: COMPLETE
πŸ“ Provide Detailed Feedback

Gene Description

FabV (PA2950) is the triclosan-resistant enoyl-[acyl-carrier-protein] reductase of Pseudomonas aeruginosa, a member of the TER/FabV family unrelated in sequence to FabI. It catalyses the NADH-dependent reduction of trans-2-enoyl-ACP to acyl-ACP, the last step of each elongation cycle of type II fatty acid synthesis, acting on enoyl-ACPs from C4 to C16; it also reduces crotonyl-CoA, but much more slowly. P. aeruginosa has a second, triclosan-sensitive enoyl-ACP reductase (FabI), and FabV is the main one: its deletion lowers enoyl-ACP reductase activity in cell extracts, slows growth, shifts the membrane towards unsaturated fatty acids, and makes the bacterium more than 2000-fold more sensitive to triclosan. Through its supply of acyl-ACPs, loss of FabV also reduces acyl-homoserine lactone quorum-sensing signal production, swarming and virulence-factor output.

Existing Annotations Review

GO Term Evidence Action Reason
GO:0004318 enoyl-[acyl-carrier-protein] reductase (NADH) activity
IBA
GO_REF:0000033
ACCEPT
Summary: IBA from PTN002206122 (FabV clade; 3 seeds, 7 leaf IBAs in 6 taxa). Seeds are V. cholerae FabV (Q9KRA3, IDA PMID:18032386), Y. pestis FabV (Q8Z9U1, IDA PMID:22244758) and P. aeruginosa FabV itself (UniProt IDA PMID:19933806; PseudoCAP IMP PMID:27965638).
Reason: The node term suits a FabV clade; all three seeds have purified-enzyme evidence, so the IBD stands without the PseudoCAP row. FabV among its own sources reflects its own IDA.
Supporting Evidence:
PMID:19933806
The addition of PaFabV, PaFabI, or EcFabI plus NADH to the reaction mixture yielded butyryl-ACP
GO:0004318 enoyl-[acyl-carrier-protein] reductase (NADH) activity
IDA
PMID:19933806
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due t...
ACCEPT
Summary: UniProt IDA; purified P. aeruginosa FabV reduces enoyl-ACPs with NADH.
Reason: Direct activity assay on the purified enzyme, with kinetics on trans-2-decenoyl-ACP.
Supporting Evidence:
PMID:19933806
The addition of PaFabV, PaFabI, or EcFabI plus NADH to the reaction mixture yielded butyryl-ACP
GO:0004318 enoyl-[acyl-carrier-protein] reductase (NADH) activity
IEA
GO_REF:0000120
ACCEPT
Summary: UniRule/EC 1.3.1.9 mapping.
Reason: Agrees with the purified-enzyme evidence.
Supporting Evidence:
file:PSEAE/fabV/fabV-uniprot.txt
HAMAP; MF_01838; FabV_reductase; 1.
GO:0004318 enoyl-[acyl-carrier-protein] reductase (NADH) activity
IMP
PMID:27965638
Functional Characterization of Triclosan-Resistant Enoyl-acy...
ACCEPT
Summary: PseudoCAP IMP, a PTN002206122 seed row. Enoyl-ACP reductase activity in cell-free extracts of the fabV deletion strain fell to about a third of wild type and rose on complementation.
Reason: Full text read. Loss of activity in a mutant lysate would alone be weak evidence for the gene's own activity, but here the activity lost is exactly the one shown for the purified enzyme (PMID:19933806), the residual activity is explained by FabI, and complementation restores activity. The term is correct for FabV; seed verdict SOUND.
Supporting Evidence:
PMID:27965638
The ENR activity (in ΞΌmol/min per mg extract protein) in cell-free extract of PAO170 was 0.175 Β± 0.006, and was lower than that in the cell-free extract of wild-type strain PAO1 (0.478 Β± 0.032).
GO:0006633 fatty acid biosynthetic process
IBA
GO_REF:0000033
ACCEPT
Summary: IBA fatty acid biosynthetic process from the FabV clade.
Reason: FabV performs the enoyl reduction step of each FAS II elongation cycle; the fabV mutant has a reduced fatty acid synthetic rate.
Supporting Evidence:
file:PSEAE/fabV/fabV-uniprot.txt
Involved in the final reduction of the elongation cycle of fatty acid synthesis (FAS II).
GO:0006633 fatty acid biosynthetic process
IDA
PMID:19933806
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due t...
ACCEPT
Summary: UniProt IDA; FabV reconstitutes the enoyl reduction step of fatty acid synthesis in vitro.
Reason: Core process; FabV catalyses a step of it.
Supporting Evidence:
PMID:19933806
The addition of PaFabV, PaFabI, or EcFabI plus NADH to the reaction mixture yielded butyryl-ACP
GO:0006633 fatty acid biosynthetic process
IEA
GO_REF:0000120
ACCEPT
Summary: UniRule/UniPathway mapping.
Reason: Consistent with the experimental evidence.
Supporting Evidence:
file:PSEAE/fabV/fabV-uniprot.txt
Involved in the final reduction of the elongation cycle of fatty acid synthesis (FAS II).
GO:0016491 oxidoreductase activity
IEA
GO_REF:0000002
TOO GENERAL
Summary: InterPro2GO oxidoreductase activity from the trans-2-enoyl-CoA reductase signature.
Reason: True but entailed by GO:0004318 enoyl-[acyl-carrier-protein] reductase (NADH) activity, which this review accepts as the core function.
Supporting Evidence:
file:PSEAE/fabV/fabV-uniprot.txt
InterPro; IPR010758; Trans-2-enoyl-CoA_reductase.
GO:0050343 trans-2-enoyl-CoA reductase (NADH) activity
IBA
GO_REF:0000033
KEEP AS NON CORE
Summary: IBA trans-2-enoyl-CoA reductase (NADH) from V. cholerae FabV and P. aeruginosa FabV.
Reason: Purified FabV reduces crotonyl-CoA, a genuine secondary activity shared with the TER family, but its Vmax with crotonyl-CoA is about 30-fold lower than with trans-2-decenoyl-ACP, and the physiological substrate is enoyl-ACP.
Supporting Evidence:
file:PSEAE/fabV/fabV-uniprot.txt
Vmax=7.9 nmol/min/mg enzyme for reductase activity with crotonyl-CoA
GO:0050343 trans-2-enoyl-CoA reductase (NADH) activity
IDA
PMID:19933806
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due t...
KEEP AS NON CORE
Summary: UniProt IDA; purified FabV reduces crotonyl-CoA with NADH.
Reason: Real but secondary activity (see the IBA row).
Supporting Evidence:
PMID:19933806
The experimentally observed maximal velocities of FabV with crotonyl-CoA and trans -2-decenoyl-ACP were higher than the maximal velocities of FabI with the same substrates
GO:0050343 trans-2-enoyl-CoA reductase (NADH) activity
IEA
GO_REF:0000120
KEEP AS NON CORE
Summary: EC 1.3.1.44 mapping.
Reason: Consistent with the IDA row; secondary activity.
Supporting Evidence:
file:PSEAE/fabV/fabV-uniprot.txt
Vmax=7.9 nmol/min/mg enzyme for reductase activity with crotonyl-CoA
GO:0051287 NAD binding
IBA
GO_REF:0000033
KEEP AS NON CORE
Summary: IBA NAD binding from the FabV clade.
Reason: FabV uses NADH as its reductant, so NAD binding is true; it is the cofactor of the core reductase activity rather than a function in its own right.
Supporting Evidence:
PMID:19933806
The addition of PaFabV, PaFabI, or EcFabI plus NADH to the reaction mixture yielded butyryl-ACP
GO:0051287 NAD binding
IDA
PMID:19933806
Triclosan resistance of Pseudomonas aeruginosa PAO1 is due t...
KEEP AS NON CORE
Summary: UniProt IDA NAD binding (NADH-dependent activity).
Reason: Cofactor binding underlying the core activity.
Supporting Evidence:
PMID:19933806
The addition of PaFabV, PaFabI, or EcFabI plus NADH to the reaction mixture yielded butyryl-ACP
GO:0051287 NAD binding
IEA
GO_REF:0000104
KEEP AS NON CORE
Summary: UniRule mapping.
Reason: As for the IBA and IDA rows.
Supporting Evidence:
file:PSEAE/fabV/fabV-uniprot.txt
Pfam; PF12242; Eno-Rase_NADH_b; 1.

Core Functions

Triclosan-resistant NADH-dependent enoyl-ACP reductase that performs the final reduction of each elongation cycle of type II fatty acid synthesis; the main enoyl-ACP reductase of P. aeruginosa.

Supporting Evidence:
  • PMID:19933806
    The addition of PaFabV, PaFabI, or EcFabI plus NADH to the reaction mixture yielded butyryl-ACP

References

Loading supporting content…

Download this section (compressed HTML)

Suggested Questions for Experts

Q: How are enoyl-ACP intermediates partitioned between FabV and FabI in P. aeruginosa, and does either isozyme favour particular chain lengths or the unsaturated branch?

Suggested Experiments

Experiment: Measure kcat/Km of purified FabV and FabI on enoyl-ACPs of each chain length, and profile acyl-ACP pools in fabV and fabI mutants by mass spectrometry.

πŸ“š Additional Documentation

Notes

(fabV-notes.md)

Loading supporting content…

Download this section (compressed HTML)

πŸ“„ View Raw YAML

Loading supporting content…

Download this section (compressed HTML)